Informational Blogs We Can Answer Any Further Questions You Have, Call Us Today.

Dangerous drugs: Is Zohydro unsafe for New York residents?

Doctors throughout the United States, including in New York, are concerned over a new medication that recently received FDA approval. The medication is scheduled to hit pharmacy shelves on March 1. It is intended to be used as a painkiller; and, according to many doctors, it should be classified among the many other types of dangerous drugs that are currently on the market.

The prescription medication that has so many up in arms is known as Zohydro. Opponents against its release claim that it is extremely addictive. Even the FDA, which approved of its use, has issued warnings that the drug could lead to death, even when used as directed.

Citing health concerns, more than 40 different medical and consumer advocacy organizations have requested the FDA to reverse its approval of the drug. Many expect that the powerful painkiller will increase the number of people who are addicted to pain pills. Indeed, considering that the release of this medication has caused so much uproar so early in its existence, it is worrisome to think what other dangerous drugs the FDA could knowingly approve.

The fact is that dangerous drugs are being sold to consumers right now. With some drugs, such as Zohydro, certain dangers are already known; however, many drugs are marketed as completely safe to consumers, even though they could cause serious debilitation and/or injury to unsuspecting victims. New York residents who suspect they or a loved one was injured because of a dangerous medication can investigate the strengths and weaknesses associated with pursuing a personal injury lawsuit. If successfully litigated, a dangerous drugs lawsuit could help victims receive money to pay for much needed medical services relating to their injury. Victims may also be able to receive restitution for other financial and emotional damages caused by the drug.

Source:, Dangerous drug Zohydro hits market on March 1, Randy Escamilla, Feb. 28, 2014